NiKogene is an off-the-shelf cryopreserved Donor-derived allogeneic NK cells , for the treatment of hematologic malignancies and solid tumors.

a phase I study of  NiKogene for the treatment of pediatrics with brain glioma  was initiated in Kian Immune Cell Company in collaboration with Royan Institute and Rasoul Akram Hospital in November 2021. The NiKogene trial will enroll 10 glioma pediatric patients , with non-surgical cerebral gliomas, DIPG, and gliomas with recurrent and resistance to chemotherapy, are treated with NiKogene cell, to evaluate the safety and efficacy of these cells in reducing tumor and Patients’ survival is investigating.